W
Wei Wei Prior
Researcher at Genentech
Publications - 28
Citations - 1967
Wei Wei Prior is an academic researcher from Genentech. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Cancer. The author has an hindex of 16, co-authored 23 publications receiving 1831 citations.
Papers
More filters
Journal ArticleDOI
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
Michael Degtyarev,Ann De Mazière,Christine Orr,Jie Lin,Brian Lee,Janet Tien,Wei Wei Prior,Suzanne van Dijk,Hong Wu,Daniel C. Gray,David Davis,Howard M. Stern,Lesley J. Murray,Klaus P. Hoeflich,Judith Klumperman,Lori Friedman,Kui Lin +16 more
TL;DR: It is shown that silencing Akt1 alone, or any combination of Akt isoforms, can suppress the growth of tumors established from phosphatase and tensin homologue–null human cancer cells, and suggests that blocking lysosomal degradation can be detrimental to cancer cell survival when autophagy is activated.
Journal ArticleDOI
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Carol O'Brien,Jeffrey Wallin,Deepak Sampath,Debraj GuhaThakurta,Heidi Savage,Elizabeth Punnoose,Jane Guan,Leanne Berry,Wei Wei Prior,Lukas C. Amler,Marcia Belvin,Lori Friedman,Mark R. Lackner +12 more
TL;DR: Gen expression studies identified a collection of genes whose expression was associated with in vitro sensitivity to GDC-0941, and expression of a subset of these genes was found to be intimately linked to signaling through the pathway.
Journal ArticleDOI
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Jeffrey Wallin,Kyle A. Edgar,Jane Guan,Megan Berry,Wei Wei Prior,Leslie Lee,John Lesnick,Cristina Lewis,Jim Nonomiya,Jodie Pang,Laurent Salphati,Olivero Alan G,Daniel P. Sutherlin,Carol O'Brien,Jill M. Spoerke,Sonal Patel,Letitia Lensun,Robert Kassees,Leanne Ross,Mark R. Lackner,Deepak Sampath,Marcia Belvin,Lori Friedman +22 more
TL;DR: GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.
Journal ArticleDOI
Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
Daniel P. Sutherlin,Linda Bao,Megan Berry,Georgette Castanedo,Irina Chuckowree,Jenna Dotson,Adrian Folks,Lori Friedman,Richard Goldsmith,Janet L. Gunzner,Timothy P. Heffron,John Lesnick,Cristina Lewis,Simon Mathieu,Jeremy Murray,Jim Nonomiya,Jodie Pang,Niel Pegg,Wei Wei Prior,Lionel Rouge,Laurent Salphati,Deepak Sampath,Qingping Tian,Vickie Tsui,Nan Chi Wan,Shumei Wang,Binqing Wei,Christian Wiesmann,Ping Wu,Bing-Yan Zhu,Alan G. Olivero +30 more
TL;DR: The discovery of 2 (GDC-0980), a class I PI3K and mTOR kinase inhibitor for oncology indications, has demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clinical trials for cancer.
Journal ArticleDOI
Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
Chudi Ndubaku,Timothy P. Heffron,Steven T. Staben,Matthew Baumgardner,Nicole Blaquiere,Erin K. Bradley,Richard James Bull,Steven Do,Jennafer Dotson,Danette Dudley,Kyle A. Edgar,Lori Friedman,Richard A. Goldsmith,Robert Heald,Aleksandr Kolesnikov,Leslie Lee,Cristina Lewis,Michelle Nannini,Jim Nonomiya,Jodie Pang,Steve Price,Wei Wei Prior,Laurent Salphati,Steve Sideris,Jeffery J. Wallin,Lan Wang,Binqing Wei,Deepak Sampath,Olivero Alan G +28 more
TL;DR: By lowering the intrinsic clearance, a set of imidazobenzoxazepin compounds are derived that showed improved unbound drug exposure and effectively suppressed growth of tumors in a mouse xenograft model at low drug dose levels.